文献速递角膜与眼表疾病

培养人角膜内皮细胞注射治疗DSAEK术后内皮移植失败

Cultured Human Corneal Endothelial Cell Injection for Endothelial Graft Failure After DSAEK.
PubMed 文献 · JAMA Ophthalmol · 2026-01-01

这项前瞻性病例系列纳入4例DSAEK术后内皮移植失败眼,接受培养人角膜内皮细胞(HCEC)前房注射。术后3个月平均BCVA从1.93 logMAR改善至0.46 logMAR,CCT从900 µm降至641 µm;2眼出现黄斑囊样水肿并经局部双氯芬酸及球周曲安奈德处理。提示该疗法对此类患眼可能可行,但样本小且无对照。

要点

  • 4例DSAEK移植失败眼接受培养HCEC注射后3个月视力与角膜厚度均改善。
  • 术后3个月平均ECD为2150 cells/mm2,术前因严重角膜水肿无法测量。
  • 2眼出现黄斑囊样水肿,经局部双氯芬酸和球周曲安奈德处理。

核心结论

  • 培养HCEC移植可能成为DSAEK术后内皮移植失败眼的一种可行选择,但证据限于4眼且无对照。

研究设计与样本

  • 前瞻性病例系列,纳入2025年东京齿科大学市川综合医院连续4例DSAEK术后内皮移植失败眼,接受培养HCEC前房注射。
  • 4例患者平均(SD)年龄68.8(9.3)岁,男性3例(75%)。

主要发现

  • 平均(SD)BCVA从术前1.93(0.59)(Snellen 20/1700)改善至3个月0.46(0.64)(Snellen 20/60),平均变化-1.46 logMAR(15行Snellen;95%CI -1.87至-1.05)。
  • 平均(SD)CCT从术前900(152)µm降至3个月641(72)µm,平均(SD)变化-260(73)µm(95%CI -483至-36 µm)。
  • 平均(SD)ECD术前因严重角膜水肿无法测量,1个月为1480(989)cells/mm2,3个月为2150(723)cells/mm2。
  • 平均(SD)IOP从术前10(2.1)mmHg变为3个月13(5.2)mmHg,平均(SD)变化+3.5(2.1)mmHg(95%CI -7.6至14.6 mmHg)。
  • 2眼出现黄斑囊样水肿,经局部双氯芬酸和球周曲安奈德注射处理;未观察到眼压升高、感染或移植片脱离等其他术中术后并发症。

临床怎么用

  • 对DSAEK术后内皮移植失败眼,培养HCEC注射可能作为再生性替代方案考虑,但需向患者说明证据仅为4例无对照病例系列。
  • 术后需监测黄斑囊样水肿,本系列中2眼发生并经局部双氯芬酸及球周曲安奈德处理。

局限性

  • 仅纳入4眼且无对照组,结论需更大样本、对照研究和更长随访确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Endothelial graft failure after Descemet stripping automated endothelial keratoplasty (DSAEK) is a clinically relevant problem, and the current standard treatment is repeat keratoplasty, which carries risks of surgery-related complications and depends on donor availability. Cultured human corneal endothelial cell (HCEC) therapy injection represents a potentially regenerative alternative; however, safety and outcomes for failed DSAEK grafts have not been reported. OBJECTIVE: To evaluate clinical outcomes of cultured HCEC therapy in eyes with endothelial graft failure after prior DSAEK. DESIGN, SETTING, AND PARTICIPANTS: This prospective case series included 4 consecutive eyes with DSAEK graft failure treated with cultured HCEC therapy at Tokyo Dental College Ichikawa General Hospital in 2025. EXPOSURE: Intracameral injection of cultured HCEC therapy for endothelial dysfunction after DSAEK. MAIN OUTCOMES AND MEASURES: Best-corrected visual acuity (BCVA, in logMAR [Snellen equivalent]), central corneal thickness (CCT), endothelial cell density (ECD), and intraocular pressure (IOP). RESULTS: A total of 4 eyes from 4 patients (mean [SD] age, 68.8 [9.3] years; 3 male [75%]) were included in this study. Mean (SD) BCVA improved from 1.93 (0.59) (Snellen, 20/1700) preoperatively to 0.46 (0.64) (Snellen, 20/60) at 3 months, with a mean change of -1.46 logMAR (15 Snellen lines; 95 CI, -1.87 to -1.05). Mean (SD) CCT changed from 900 (152) µm preoperatively to 641 (72) µm at 3 months with mean (SD) changes of -260 (73) µm (95% CI, -483 to -36 µm). Mean (SD) ECD could not be measured preoperatively because of severe corneal edema and was 1480 (989) cells/mm2 at 1 month and 2150 (723) cells/mm2 at 3 months. Mean (SD) IOP changed from 10 (2.1) mm Hg preoperatively to 13 (5.2) mm Hg at 3 months, with a mean (SD) change of +3.5 (2.1) mm Hg (95% CI, -7.6 to 14.6 mm Hg). Cystoid macular edema was observed in 2 eyes and was managed with topical diclofenac and sub-Tenon injections of triamcinolone acetonide. No other intraoperative and postoperative complications, including IOP elevation, infection, or graft detachment, were observed. CONCLUSIONS AND RELEVANCE: Although limited to 4 eyes without controls, these findings suggest that cultured HCECs transplantation may be a feasible option for eyes with DSAEK graft failure. Confirmation in larger, controlled studies with longer follow-up is warranted.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ogino R, Shirane M, Shijo T, et al. Cultured Human Corneal Endothelial Cell Injection for Endothelial Graft Failure After DSAEK. JAMA Ophthalmol. 2026. PMID: 41989809. doi:10.1001/jamaophthalmol.2026.0812

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。